Supplementary Figure 1. Schematic representation and dose-response curves of different recombinase switches. a | Mechanistic illustration of the underlying recombination processes indicating the region of interest (ROI) being modified by a recombinase and the site-specific recombination sites (blue triangles). b | Detailed description of the recombinase switches. In order to express a target gene, the switch construct (left) has to undergo sitespecific recombination. Triangles indicate recombinase recognition sites. The PhiC31-Inversion Switch is based on non-identical sites attP and attB and is thus intrinsically irreversible because post-recombination sites are different from the original ones. The Cre Excision Switch is irreversible because the excision of GFP by flanking loxP sites places DsRed in frame and back integration is extremely inefficient. The Flex Switch is irreversible because it contains two pairs of distinct sites. This is a two-step process involving inversion and excision, leaving a pair of heterospecific sites (loxP and lox2272 for Cre and FRT and F3 for FlpO) that cannot both serve as a substrate for intramolecular reaction. Only after successful recombination, the construct (right) is able to express the target gene. The resulting constructs on the right were pre-made to serve as a positive control. c | Doseresponse of the individual switches. In order to test recombination performance of the different recombinases, PhiC31, Cre and FlpO driven by a constitutive promoter Ef1a were cotransfected with either the switch construct (orange dots) or the pre-recombined construct (red dots) and a transfection control. Each dot represents mean±SD from three biological replicates measured 48 hours after transfection by flow cytometry. The efficiency (black dots) is calculated as the ratio between recombinase-triggered response and the response of prerecombined control in the presence of the same recombinase amount. The curves serve as visual guides (drawn manually). Orange and black circles indicate data point with maximal switch response and the corresponding efficiency, respectively. Both data points were used to create bar chart in Fig. 2b . Plasmid amounts are provided in Supplementary Table 1 
Left to right: circuit code names; presence or absence of the miRNA mimics; Cerulean and Citrine intensities shown as mean±SD from three independent biological replicates; representative microscopy snapshots showing the Citrine expression (Yellow pseudocolor) and the transfection marker mCherry expression (Red pseudocolor). Cerulean snapshots are not shown due to very low Cerulean signal because of low plasmid dosage. The snapshot series correspond to the configurations in the table on the left and the name of the circuit is also indicated below the images for easier orientation. Statistical significance of Citrine response between Off-samples (-/-, +/+, -/+) and On-samples (+ / -) are indicated as follows: **p<0.000001, *p<0.0001. P-Values were calculated using a two-sided unpaired t-test. Transfection setup is given in Supplementary Table 6 and the summary of quantitative readouts in Supplementary Table 11 Gating strategy used to process flow cytometry data. Living cells were selected based on forward and side scatter properties. For scatter plot visualization, equal numbers of cells were selected using time gate. If necessary, channels were compensated before fluorescent-positive cells were gated with the help of single color transfection controls using a threshold of 0.01% positive cells in the gate.
Supplementary Tables
Supplementary Table 1 . Transfection setup of the recombinase titration shown in Supplementary Fig. 1 . The numbers are the nanogram (ng) plasmid amounts co-transfected per sample in a 24-well setup. Samples used to generate Fig. 2b are highlighted. Red: samples, which generated the highest switch response, grey: corresponding positive control used to calculate the efficiency. The nanogram (ng) amounts of the plasmids co-transfected per sample in a 24-well setup are given. Samples highlighted in red generated the highest switch response ("+" data point in Fig. 2d ). Samples in grey were used to calculate the leakage of the promoter ("-" data point in Fig. 2d ). Listed are the mean values of the normalized Citrine response (r.u., see Methods) of the flexed target (Switch) and the pre-recombined target construct (Pos. Ctrl.) with the corresponding standard deviation (SD). a) The Off state obtained in the absence of an activator, the peak response of the switch and the amount of an activator triggering this response, target expression from pre-recombined positive control with same amount of activator, and the switch efficiency. The activator amount at a peak response is shown in the column Act. b) Target expression from the pre-recombined construct when no transactivator is present and with maximal amount of transactivator used (120 ng) with the corresponding reduction in target expression shown in a separate column. OFF = no transactivator, ON max = peak response, Activator max = response at highest amount of transfected transactivator, 120 ng Fig. 3b and 3c The nanogram (ng) amounts of the plasmids transfected per sample in a 24-well setup are given. microRNA mimics are given in the final concentration used per sample in nanomolar units (nM). The nanogram (ng) amounts of the plasmids transfected per sample in a 24-well setup are given. microRNA mimics are given in the final concentration used per sample in nanomolar units (nM).
PhiC31-Inversion
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Supplementary Table 4. Transfection setup of the Cerulean-2A-PIT2 titration (a) and the miR-21 sensor titration (b) as shown in
Supplementary
Supplementary Table 6 . Transfection setup of Second iteration circuits (V2) performance characterization as shown in Fig. 5c . CAGop-lox2272-loxPmCerulean 2A PITrev-T141 T142-T146a-lox2272-loxP-TFF4 (pEL0167) 120  120  120  120  120  120  120  120  120  120  120  120  120  120  120  120  120  120  120  120  120  120  120  120  120  120 miR-21 mimic The nanogram (ng) amounts of the plasmids co-transfected per sample in a 24-well setup are indicated. Amounts of microRNA mimics and antibiotic Doxycycline are given as the final concentration used per sample in nanomolar units (nM) and μg/ml respectively. The numbers are given in relative expression units (r.u., see Methods) and they represent a mean value of three independent replicates together with the corresponding standard deviation (SD). On:Off ratios are calculated after background subtraction using ΔPIT2 (and Cerulean-negative) control circuits to correct for Cerulean autofluorescence, and ΔPIR control circuits (indistinguishable in their Citrine expression from Citrine-negative samples) to correct for Citrine autofluorescence. For samples with the calculated Off levels lower than autofluorescence, the On:Off ratio is set at >1000 given the number of significant digits in our data. Table 8 . Transfection setup of First iteration circuit (V1) performance characterization as shown in Supplementary Fig. 6 .
CMV-rtTA-T21 (pZ090) CAGop-mCerulean 2A PIT-T141 T142-T146a-TFF4 (pEL0157) CMV-lox2272-loxP-mCitrinerevlox2272-loxP (pEL0098) The numbers are given in relative expression units (r.u., see Methods) and they represent a mean value of three independent replicates together with the corresponding standard deviation (SD). On:Off ratios are calculated from after background subtraction using ΔPIT2 (and Ceruleannegative) control circuits to correct for Cerulean autofluorescence, and ΔPIR control circuits (indistinguishable in their Citrine expression from Citrine-negative samples) to correct for Citrine autofluorescence. For samples with the calculated Off levels lower than autofluorescence, the On:Off ratio is set at >1000 given the number of significant digits in our data. Transfections were performed in a 6-well plate setup. DNA amounts are given in nanogram (ng). microRNA mimics are given in nanomolar (nM) and antibiotics Doxycycline, Pristinamycin and Erythromycin in μg/ml. Both are given as the final concentration used per reaction. The values are given in relative expression units (r.u., see Methods) indicating the mean value of three independent replicates and the corresponding standard deviation (SD).
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Supplementary Table 14 The nanogram (ng) amounts of the plasmids co-transfected per sample in a 24-well setup are indicated. Doxycycline was added to all samples at a concentration of 1 μg/ml. The numbers are given in relative expression units (r.u., see Methods) and they represent a mean value of three independent replicates together with the corresponding standard deviation (SD). In order to estimate the recombination efficiency for a given amount of recombinase, we constructed pre-recombined positive controls. We then performed dose-response measurements by varying the amount of constitutively-expressed recombinase with fixed switch and control constructs to measure absolute target levels and relative recombination efficiency using pre-recombined controls as the reference.
Supplementary
Quantitative analysis of flow cytometry data ( Supplementary Fig. 2c ) showed that the different switches varied widely in dose-response. The PhiC31-inversion and the Creexcision were found to be highly inefficient with similar low absolute target expression of 6.34x10 -3 and 9.75x10 -3 relative expression units (r.u.), respectively. Measured recombination efficiency was 2% for the PhiC31-inversion and 30% for the Cre-excision due to a large difference in the expression levels of the corresponding positive controls.
On the other hand, the Cre-Flex and FlpO-Flex switches had maximal recombination efficiencies of 62% and 52%, respectively. More importantly, both recombinase switches reached high absolute responses of 0.51 and 0.45 r.u., respectively, about two orders of magnitude higher than the absolute responses of the PhiC31-Inversion and the CreExcision switches.
Supplementary Note 2: Transfection Characteristics of HEK293
Investigation of different transfection controls used in various circuit-relevant figures shows that circuit configuration, especially the amount and combination of cotransfected plasmids, do not influence transfection efficiency ( Supplementary Fig. 12a ). In the majority of our samples we observed efficiencies of >77% using transfection control Ef1a-Cherry and CMV-iRFP and > 60% using CMVCherry. Further investigation of constitutive expression cassette Ef1a-Cerulean, cotransfected with different amounts of other constitutively driven expression units ( Supplementary Fig. 12b ), reveals that the amount of transfected DNA has no significant influence on the frequency of Cerulean-positive cells. However, the mean intensity of Cerulean was reduced in the presence of other protein-expressing plasmids but not in the presence of transcriptionally-inactive Junk DNA. Therefore we believe that the decrease in Cerulean expression is due to competition for transcriptional/translational machinery in the cell. To follow up on this observation, we analyzed the behavior of transfection control Ef1a-Cherry in miR-21 sensor titration assay shown in Fig. 4b , where the amount of a constitutive expression unit (CMV-rtTA-T21) and an induced expression unit (pTRE-LacI-T21) were varied ( Supplementary Fig. 12c ). In agreement with Supplementary Fig. 12b , the frequency of cells positive in the transfection control reporter is not significantly reduced while the mean value are reduced by half with the addition of 240 ng plasmid.
We note that highest titration point (750 ng) is slightly above our optimal transfection condition.
Both analyses (Fig. 12b,c) indicate that the cell's transcriptional and/or translational machinery is the limiting factor when a high amount of transcriptionally active DNA is used. We therefore include the mean value of the transfection control in our normalization procedure (see Methods), therefore compensating for this effect. Experiments testing for recombinase specific inhibition ( Supplementary Fig. 3 ) indicates that our normalization procedure distinguishes non-specific effects from specific inhibition.
The observed reduction of output level in circuits with more plasmids (compare Supplementary Fig. 7 to Fig. 5 to Fig. 6 ) arises i) from imperfect recombination at the knot level as evidenced from control circuit measurements and ii) from a general reduction in frequency of cell that contain all circuit genes simultaneously ( Supplementary Fig. 4 ).
Supplementary Methods
Plasmid Construction
Ef1α -mCerulean (pKH024): mCerulean was PCR amplified from Addgene plasmid 30128 (pKH017) with primers PR0446 and PR0447 and cloned into Addgene plasmid 11154 (pKH013) using EcoRI and EagI restriction sites.
Ef1α-mCitrine (pKH025): mCitrine was PCR amplified from Addgene plasmid 30126 (pKH016) with primers PR0505 and PR0451 and cloned into Addgene plasmid 11154 (pKH013) using EcoRI and EagI restriction sites.
Ef1α-mCherry (pKH026): mCherry was PCR amplified from Addgene plasmid 30125 (pKH015) using primers PR0504 and PR0550 and cloned into Addgene plasmid 11154 (pKH013) after digestion with EcoRI and EagI.
CMV-Cherry (pEL0208):
Coding region of pBH016 (CMV-ZsYellow, BD pZsYellow1-N1, #632445) was replaced by coding region mCherry from pKH026 using EcoRI and NotI.
PGK-FLpO-BGHpA-Ef1α-iCre-SV40pA (pKH012): Addgene plasmid 26745.
Ef1α-phiC31o (pEL0191):
PhiC31o was PCR amplified from Addgene plasmid 13795 (pKH003) using primers PR0613 and PR1346 and cloned into pKH026 using EcoRI and NotI restriction sites.
Ef1α-FlpO (pEL0162):
FlpO was PCR amplified from Addgene plasmid 26745 (pKH012) using primers PR0970 and PR0971 and cloned into pKH025 using EcoRI and XbaI.
Ef1α-iCre (pNL108) Addgene plasmid 26745 (pKH012) was digested with HindIII in order to remove the PGK-FlpO expression cassette to produce Ef1α-iCre (pEL0154).
Ef1α-Cre was excised from pEL0154 using SpeI and HindIII in order to replace the backbone with the backbone from CAGop-dsRed-FF5 (pZ223, Xie et al. with PR0957 and PR0958 and cloned into pEL0185 using AgeI and HindIII.
PIR tight -iCre (pEL0105): The construct was cloned using standard procedures, using intermediate building blocks that will be described elsewhere (Angelici et al, in preparation). The construct was sequenced-verified and the map is available upon request.
PIR tight -FlpO (pEL0160): pEL0105 was cut with AgeI and HindIII in order to remove iCre.
The coding region of FlpO was PCR amplified from pKH012 with PR0957 and PR0958
and cloned into pEL0105.
LEX tight -iCre (pEL0184):
The construct was cloned using standard procedures, using intermediate building blocks that will be described elsewhere (Angelici et al, in preparation). The construct was sequenced-verified and the map is available upon request.
LEX tight -FlpO (pEL0192): FlpO was PCR amplified from pKH012 with PR0957 and PR0958 and cloned into pEL0184 using AgeI and HindIII.
CMV-dsRed (pBH0015): pDsRed-Express-C1 from BD (Cat # 632430) PIR tight -dsRed (pEL0171): DsRed was extracted from pBH0015 using AgeI and HindII and cloned into pBA076 by AgeI and HindIII.
PIR tight-Citrine (pEL0172): Coding region of mCitrine was PCR amplified from pKH025 using primers PR1055 and PR1056 and cloned into pBA076 using AgeI and HindIII.
CMV-iRFP (pCS012): Addgene plasmid 31857
CMV-loxP-EGFP-loxP-dsRed (pEL0086): Addgene plasmid 8389
CMV-loxP-dsRed (pEL0194): pEL0086 was in vitro treated with Cre recombinase according to manufacturer protocol (NEB).
attP-CMV rev -attB-dsRed (pEL0041): CMV was PCR amplified from pBH0015 using forward primer PR0185 harboring the reverse complement of the attB sequence and reverse primer PR0186 harboring the attP site. Both primers include SapI restriction sites designed such that the sequence is inverted after ligation. The backbone of pBH0015 excluding CMV was PCR amplified with primer PR0187 and PR0188 including SapI restriction sites. AttP (38bp) and attB (35 bp) sequences were derived from Groth et al.
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attR-CMV for -attL-dsRed (pEL0062): pEL0041 and pPGK-phiC31obpA (Addgene plasmid 13795) were cotransfected into Hela cells. DsRed-positive cells were sorted 48 hours after transfection and DNA was extracted using DNeasy Kit Blood and Tissue (Quiagen). PCR was performed using primer PR0438 and PR0439 in order to amplify the whole attL-CMV-attR-dsRed cassette which was subsequentially cloned into AmCyan-TRE-DsRed (pZ060, Xie et al. 1 ) in order to produce AmCyan-attL-CMV-attR-dsRed (pEL0053). pEL0053 was digested with XbaI and EcoRI in order to remove AmCyan. The 5'-ends were filled up using DNA Polymerase I, Klenow (Large) Fragment (NEB) to create blunt ends and allow ligation.
CMV-lox2272-loxP-Citrine rev -lox2272-loxP (pEL0098): lox2272-loxP-mCitrine revlox2272 was PCR amplified from Addgene plasmid 28304 (pEL0087) using PR0710 and PR0711 and cloned into pBH0015 backbone using AgeI and HindIII.
CMV-lox2272-mCitrine for -loxP (pEL0158): pEL0098 was in vitro treated with Cre recombinase (NEB).
CMV-F3-FRT-mCitrine rev -F3-FRT (pEL0176):
FRT-F3-mCitrine-miR145 rev FRT-F3 was synthesized by GeneScript; FRT and F3 were designed according to Schnuetgen et al. 6 and mCitrine miR145 was designed according to CMV-lox2272-loxP-mCitrine-miR145 revlox2272-loxP (pEL0146) (not described here) where mCitrine is based on two exons interrupted with an intron encoding the natural hsa-miR-145 from BAC RP11-699D5. The synthesized cassette was cloned into pBH0015 using AgeI and SalI. The produced construct CMV FRT-F3-mCitrine miR145 rev FRT-F3 (pEL0166) was cut with XhoI and NotI in order to replace mCitrine-miR145 with mCitrine, which was PCR amplified with primers PR1141 and PR1142 from pKH025.
CMV-F3-FRT-DsRed-F3-FRT (pEL0173):
FRT-F3-mCitrine miR145 rev was digested with NotI and XhoI. DsRed was PCR amplified from pBH0015 with primers PR1057 and PR1058.
CMV-F3-mCitrine-FRT (pEL0188):
CMV-F3-FRT-mCitrine rev -F3-FRT (pEL0176) and Ef1α-iCre (pEL0154) were cotransfected into HEK293 cells. Whole genome was extracted 48 hours after transfection using DNeasy Blood and Tissue Kit (Qiagen). PCR was performed on the extracted DNA with PR0825 and PR0869 in order replace the flanked mCitrine cassette in pEL0176 with AgeI and KpnI.
CAGop-mCerulean-2A-PIT rev -T141-T142-T146a-TFF4 (pEL0157): The construct was cloned using standard procedures, using intermediate building blocks that will be described elsewhere (Angelici et al, in preparation and Haefliger et al, in preparation) .
The construct was sequenced-verified and the map is available upon request.
